These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34023026)

  • 1. Hypoxia signaling in renal pericytes-is it safe to activate?
    Herbek S; Edmonston DL; Souma T
    Kidney Int; 2021 Jun; 99(6):1267-1269. PubMed ID: 34023026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
    Pan SY; Tsai PZ; Chou YH; Chang YT; Chang FC; Chiu YL; Chiang WC; Hsu T; Chen YM; Chu TS; Lin SL
    Kidney Int; 2021 Jun; 99(6):1354-1368. PubMed ID: 33812664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
    Nangaku M
    Rinsho Ketsueki; 2021; 62(8):938-943. PubMed ID: 34497234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    McMahon GM; Singh AK
    Curr Opin Nephrol Hypertens; 2019 Nov; 28(6):600-606. PubMed ID: 31567284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
    Rawee P; Eisenga MF
    Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?
    Macdougall IC
    Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):399-405. PubMed ID: 35894273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
    Wish JB
    Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360
    [No Abstract]   [Full Text] [Related]  

  • 17. EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis.
    Kobayashi H; Davidoff O; Pujari-Palmer S; Drevin M; Haase VH
    Acta Physiol (Oxf); 2022 Aug; 235(4):e13826. PubMed ID: 35491502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
    Haase VH
    Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Sugahara M; Tanaka T; Nangaku M
    Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.